作者: Mary Culnane , Ross E McKinney Jr , Sharon Nichols
DOI:
关键词:
摘要: Objectives. To compare the safety and tolerance of stavudine (d4T) versus zidovudine (ZDV, AZT) in symptomatic human immunodeficiency virusinfected children 3 months to 6 years of age.Methods. In an initially double-blind trial, 212 évalu-able human immunodeficiency virus-infected children who had received no more than 6 weeks of previous antiretroviral therapy were randomized to receive either d4T (1 mg/kg orally every 12 hours, maximum 40 mg orally every 12 hours) or zidovudine (180 mg/m2 orally every 6 hours, maximum 200 mg orally every 6 hours). The study was unblinded after a median follow-up period of 6.3 months; median follow-up at study closure was 17.3 months. Tolerance, safety, disease progression, and immunologie responses were evaluated.Results. The patient population was young (median age, 1.2 years; range, 0.3 to 6.4 years), with a median baseline CD4+ lymphocyte count of 965 cells/jxL (range, 18 to 4238 cells/jtL). Neutropenia< 400//uL occurred sig-